CPIX CUMBERLAND PHARMACEUTICALS I revenue, earnings and financials

For the quarter ended June 30, 2026, CUMBERLAND PHARMACEUTICALS I reported revenue of $166K (down 56.3% from a year earlier), net income of −$4.28M and diluted EPS of −$0.29; over the last four quarters revenue was $31.3M and net income −$10.9M; for the fiscal year ended December 2025 revenue was $44.5M, up 17.6% on the year before.

CPIX annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $44.5M, gross profit n/a, operating income −$2.79M, net income −$2.84M (margin -6.4%), EPS −$0.19
• Fiscal year ended Dec 2024: revenue $37.9M, gross profit n/a, operating income −$6.43M, net income −$6.48M (margin -17.1%), EPS −$0.46
• Fiscal year ended Dec 2023: revenue $39.6M, gross profit n/a, operating income −$9.55M, net income −$6.28M (margin -15.9%), EPS −$0.44
• Fiscal year ended Dec 2022: revenue $42.0M, gross profit n/a, operating income −$5.70M, net income −$5.57M (margin -13.3%), EPS −$0.38
• Fiscal year ended Dec 2021: revenue $36.0M, gross profit n/a, operating income −$7.68M, net income −$3.51M (margin -9.7%), EPS −$0.24

CPIX quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $166K (down 56.3% year over year), net income −$4.28M, EPS −$0.29
• Quarter ended Mar 31, 2026: revenue $9.13M (down 22.0% year over year), net income −$3.29M, EPS −$0.22
• Quarter ended Dec 31, 2025: revenue $13.7M (up 31.1% year over year), net income −$1.41M, EPS −$0.09
• Quarter ended Sep 30, 2025: revenue $8.29M (down 8.7% year over year), net income −$1.94M, EPS −$0.13
• Quarter ended Jun 30, 2025: revenue $381K (down 96.1% year over year), net income −$741K, EPS −$0.05
• Quarter ended Mar 31, 2025: revenue $11.7M (up 37.8% year over year), net income $1.26M, EPS $0.08
• Quarter ended Dec 31, 2024: revenue $10.4M (up 11.6% year over year), net income −$1.90M, EPS −$0.14
• Quarter ended Sep 30, 2024: revenue $9.09M (down 9.9% year over year), net income −$1.54M, EPS −$0.11
• Quarter ended Jun 30, 2024: revenue $9.85M (down 9.6% year over year), net income −$1.09M, EPS −$0.08
• Quarter ended Mar 31, 2024: revenue $8.50M (down 7.9% year over year), net income −$1.95M, EPS −$0.14
• Quarter ended Dec 31, 2023: revenue $9.35M (up 2.5% year over year), net income −$6.29M, EPS −$0.44
• Quarter ended Sep 30, 2023: revenue $10.1M (down 11.6% year over year), net income −$1.05M, EPS −$0.07
• Quarter ended Jun 30, 2023: revenue $10.9M (up 5.7% year over year), net income $872K, EPS $0.06
• Quarter ended Mar 31, 2023: revenue $9.22M (down 17.5% year over year), net income $192K, EPS $0.01
• Quarter ended Dec 31, 2022: revenue $9.12M (up 9.7% year over year), net income −$2.44M, EPS −$0.17
• Quarter ended Sep 30, 2022: revenue $11.4M (up 41.4% year over year), net income −$409K, EPS −$0.03
• Quarter ended Jun 30, 2022: revenue $10.3M (up 13.7% year over year), net income −$1.34M, EPS −$0.09
• Quarter ended Mar 31, 2022: revenue $11.2M (up 6.1% year over year), net income −$1.39M, EPS −$0.09
• Quarter ended Dec 31, 2021: revenue $8.32M, net income −$3.85M, EPS −$0.26
• Quarter ended Sep 30, 2021: revenue $8.07M, net income −$1.06M, EPS −$0.07

CPIX cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow $4.93M, share buybacks $263K
• Fiscal year ended Dec 2024: operating cash flow −$612K, share buybacks $579K
• Fiscal year ended Dec 2023: operating cash flow $6.09M, share buybacks $741K
• Fiscal year ended Dec 2022: operating cash flow $8.45M, share buybacks $1.05M
• Fiscal year ended Dec 2021: operating cash flow $6.34M, share buybacks $1.39M

CPIX balance sheet

• Jun 30, 2026: cash $3.86M, total assets $62.9M, total liabilities $45.8M, shareholders' equity $17.4M
• Mar 31, 2026: cash $11.0M, total assets $71.0M, total liabilities $49.7M, shareholders' equity $21.6M
• Dec 31, 2025: cash $11.4M, total assets $76.8M, total liabilities $52.3M, shareholders' equity $24.9M
• Sep 30, 2025: cash $15.2M, total assets $65.9M, total liabilities $40.1M, shareholders' equity $26.1M
• Jun 30, 2025: cash $16.1M, total assets $67.9M, total liabilities $40.2M, shareholders' equity $28.0M
• Mar 31, 2025: cash $15.1M, total assets $69.9M, total liabilities $41.6M, shareholders' equity $28.7M
• Dec 31, 2024: cash $18.0M, total assets $75.6M, total liabilities $53.0M, shareholders' equity $22.9M
• Sep 30, 2024: cash $17.5M, total assets $76.7M, total liabilities $52.3M, shareholders' equity $24.8M

What is CPIX's revenue?

CUMBERLAND PHARMACEUTICALS I reported $31.3M of revenue over its last four quarters, through June 30, 2026.

Is CPIX profitable?

No. CUMBERLAND PHARMACEUTICALS I lost $10.9M over the last four quarters.

What is CPIX's EPS?

Diluted earnings per share over the last four quarters were −$0.73; −$0.29 in the latest quarter.

CPIX ownership and insider trades · All stocks